Objective: The developmental pipeline for novel therapeutics to treat sepsis has diminished to a trickle compared to previous years of sepsis research. While enormous strides have been made in understanding the basic molecular mechanisms that underlie the pathophysiology of sepsis, a long list of novel agents have now been tested in clinical trials without a single immunomodulating therapy showing consistent benefit. The only antisepsis agent to successfully complete a phase III clinical trial was human recumbent activated protein C. This drug was taken off the market after a follow-up placebo-controlled trial (human recombinant activated Protein C Worldwide Evaluation of Severe Sepsis and septic Shock [PROWESS SHOCK]) failed to replicate the favorable results of the initial registration trial performed ten years earlier.
trials to test and develop new immunomodulating agents, anti-inflammatory agents, and antiendotoxin agents (Fig. 1) . Yet, not a single agent has convincingly proven to be consistently efficacious in clinical trials. There are no new drugs on the market to show for all this effort.
Recent failed trials with activated Protein C (5, 6), human recombinant lactoferrin (7) , and the MD2-TLR4-LPS antagonist eritoran (8) are further indicators that our basic underlying hypotheses and conventional assumptions are flawed, or the strategies employed to test these hypotheses in clinical trials are not working and need to be changed. Justifiable skepticism now pervades the field of clinical sepsis research. Hopes for real progress in bringing novel therapeutics through the regulatory phase into the clinic have dimmed, and unless some new ideas are instituted in drug discovery and evaluation process, biotechnology investments and research programs will understandably redirect their resources and energies elsewhere. We must change course in the conduct of new drug evaluation for sepsis if we hope to succeed in the future. We propose some specific and readily achievable suggestions to redirect sepsis research toward a more hopeful future ( Table 1) .
The short-and long-term consequences of sepsis already have an enormous impact on public health, and these trends are only likely to worsen in the foreseeable future (9) (10) (11) . The global expansion of vulnerable elderly patients, income disparities, and failure of the infrastructure capacity of developing nations to keep pace with the growing, increasing urbanized, human population make it likely that sepsis will increase in prevalence for the next several decades. The widespread use of immunosuppressive medications for a wide variety of indications, rising use of implantable devices, and the spread of multiple, antibiotic-resistant, microbial pathogens will collectively conspire to keep infections high on the problem lists over the next 25 years (11) . We reexamine the crucial elements in drug development for sepsis, highlight the barriers to further progress, and offer some potential solutions to move this field forward.
PRECLINICAL EVALUATION OF NEW SEPSIS TARGETS AND INTERVENTIONS: WHAT ARE WE DOING WRONG?
A dichotomous view of the pathophysiology and outcome of sepsis is evolving in both animal models and in clinical studies. Classically, human sepsis has been characterized as a hyperacute inflammatory syndrome manifest by the sudden systemic release of an array of inflammatory mediators. This presentation is mimicked in animal models of sepsis using overwhelming intoxication with endotoxin or high-grade bacteremia. A clinical example of this presentation is the dramatic, hyperacute clinical presentation seen in meningococcal septic shock or in the overwhelming postsplenectomy pneumococcal infection syndrome where a rapidly progressive syndrome runs its course over minutes to hours. However, such clinical presentations are only occasionally observed in hospitalized patients today.
More commonly, sepsis presents as a subacute illness with gradual development of multiple organ dysfunction that runs its course over days to weeks. Patients who survive this process are often left with impaired quality of life with cognitive defects and increased susceptibility to subsequent infections that persists for years (11) (12) (13) . Far less work has been done on the development of animal models that actually replicate this regrettably common chronic process seen in patient care.
There are numerous examples in which pretreatment models or models of systemic inflammation such as a lipopolysaccharide challenge or IV bolus of bacteria do not predict clinical success (14) . These models are essentially intoxication systems of acute severe inflammation and not true infection models. A fundamental difference between animal models and human sepsis is that the timing and stage of host response readily determined, yet the timing of onset and immune status of the patient presenting with severe sepsis is rarely known with precision. This simple fact induces intrinsic heterogeneity in interventional studies in human sepsis making prediction of efficacy much less accurate in clinical medicine than the animal laboratory. In some animal infection models (14, 15) , and in one clinical study (16) , anticytokine therapy actually worsened outcome. A recent transcriptome analysis comparing mouse models to the human host response to sepsis, trauma, and burns revealed almost a complete lack of correlation in host response genes between mice and humans (17) . Until we have validated models, we should be suspicious about their value and circumspect about our reliance on such models as guides to test efficacy in clinical drug development.
Animal models can still provide some limited information in the development of new sepsis drugs. Pharmacokinetics, safety, potential toxicities, and mechanisms of action can be investigated in animals and provide some margin of safety prior to exposing human volunteers to new therapies. Small animal models might be improved by the use of aged animals rather than young healthy animals, as is the current practice in most animal studies. Sepsis is primarily a disorder of older patients, and animal models should be appropriately adjusted to account for this fact. Age-related changes in adaptive Centers of excellence are optimal in phase II; but phase III study sites with variable expertise in sepsis should assess the "real-life" safety/efficacy of the experimental drug
Clinical coordinating centers can assist in phase III trials to limit variability and assure comparability across study centers 10 Study protocol entry criteria need to define a patient population at real risk for the study endpoint (e.g., death from sepsis) and some likelihood of responding to the study agent
Attributable risk for sepsis-related mortality is critical; patients at high risk of death should not be excluded, they are most likely to benefit 11 Two large clinical trials, demonstrating reproducible efficacy in sepsis trials, will likely be necessary for drug or device registration Costs are already prohibitive; an improved set of biomarkers, study design, or additional financial incentives (extended patent life) may be needed immune responses and increased susceptibility to apoptosis are well-known immunologic events that likely impact the host response to sepsis (18) . Preferably, such small animal studies should be followed by large animal models where careful hemodynamic and repeated physiologic measurements can be investigated. A more robust effort is needed in the further development of ex vivo systems (e.g., tissue explants from organ donation or in vitro polarized and functional human tissue culture systems that, in part, replicate endothelial and epithelial structure and function in vivo) and in silico models of the inflammatory response to determine if such systems can provide useful information.
THE LACK OF PRECISION IN SEPSIS DEFINITIONS: WHAT IS WRONG WITH OUR TERMINOLOGY?
Sepsis research is hampered by the lack of accurate diagnostic methodologies or readily available, predictive biomarkers to direct clinical trial design and define patient populations likely to respond to specific antisepsis interventions. The diagnostic criteria for sepsis are vague and readily confused with other medical and surgical diseases. Sepsis is not a discreet nosologic entity. Rather, it is a syndrome consisting of a constellation of signs and symptoms and laboratory features that together suggest a systemic inflammatory response related to infection accompanied by new onset organ dysfunction. Attempts to improve the diagnostic validity of the term "sepsis" and "septic shock" have been conducted since the early days when Bone et al (10, 19) first attempted to codify the clinical terminology. In a recent epidemiologic investigation, modest changes in the interpretation of infection and systemic inflammatory response syndrome (SIRS) criteria resulted in markedly different patient populations and major differences in overall mortality rate (20) . This lack of precision results in variation in defining septic patients across different centers and different clinical trials. Patient heterogeneity has been and continues to be a hallmark of sepsis populations within clinical trials. This problem remains a major impediment to defining a responsive patient population for a specific intervention, and this issue remains a major unmet medical need in clinical trial design in sepsis studies. The use of sepsis biomarkers might help but no specific single or set of proposed biomarkers has been shown to be sufficiently discriminatory to help limit heterogeneity and improve the diagnostic utility of the term "sepsis." Hopefully, efforts in computational biology and personalized medicine will define a responsive patient population for sepsis trials rather than SIRS criteria for clinical trials (21) .
Three basic strategies have been proposed to deal with the heterogeneity problem in sepsis trials: 1) conduct large, simple trial designs (mega trials) involving tens of thousands of patients to detect small but significant overall trends in large sepsis populations; 2) small, focused trials with pathogen-specific, mediator-based or an organ site-specific (e.g., severe community-acquired pneumonia, peritonitis, necrotizing soft-tissue infections, and toxic shock syndrome) clinical trial design that is focused on a more homogenous patient population; and 3) midsized, contemporaneous parallel studies in different countries or regions of the world. There are arguments in favor and against each of these approaches.
The major advantage of the large simple trial model, where tens of thousands of patients are pooled together, is the greatly enhanced statistical power to find treatment benefits over current phase III trial sample size. The large sample size also provides face validity that similar benefits would accrue to the entire population of septic patients should the drug be released on the market. However, large simple trial designs in sepsis could lose discriminating power in sepsis trials if only a subset of patients were benefited while another subgroup of patients were worsened by the same treatment intervention. This would be difficult to decipher in a mega trial where extensive details of the microbiology and physiology of each individual patient are not collected. Pathophysiological mechanisms accounting for important differences in outcome within various patient subpopulations also would be obscured.
Critics of the pathogen-specific disease model argue that a rapid diagnostic assay would be required, preferably nonculture, nucleic acid-based methods, for specific microbiologic diagnosis in critically ill patients. Such methods do not exist at present. Even if such assays became available, they still may not define a very specific patient population. Consider a pathogen such as Staphylococcus aureus that causes a much different illness and requires much different treatment and markedly varied outcome depending if the same organism is infecting the leptomeninges, heart valves, prosthetic joints, or skin and soft tissue. Additionally, single organism studies would lack external validity and could not be readily extrapolated and replicated in serious infections by other microorganisms. Identifying specific microbial or host-derived, target mediators before study entry is another approach to identify a potentially responsive patient population for future sepsis studies.
Running simultaneous, independent clinical trials with identical study protocols in different regions of the world adds general validity to the study results if both studies generate similar favorable outcomes. The combined data would indicate that a similar effect size can be expected when the therapy is approved and becomes widely available. The problem arises if the study results are positive at one region but shown not to be effective or even worse at the second regional study. Does this negate the positive results or are their mitigating factors that explain the differences in outcome in the two studies?
CAN ADAPTIVE TRIAL DESIGN IMPROVE THE SUCCESS RATE IN SEPSIS TRIALS?
Adaptive trial design has been proposed as an improved method to design and implement sepsis trials. Adaptive design is a Bayesian methodology in which multiple arms can be run simultaneously and the trial assumptions can adapt to the early findings during the enrollment process using predefined analytic rules (22) . As enrollment proceeds, patients can be preferentially randomized to the most effective arms in a multidose study, thereby reducing or eliminating the number of patients who are assigned the less effective arms. This design offers the opportunity in some instances to provide an answer about efficacy or lack of efficacy in a shorter period of time then would be possible using the standard approach. Basically, an adaptive design allows for reassessment of ongoing trial assumptions of sample size, enrollment criteria, surrogate endpoint validity, and so on using a priori planned boundaries based on early information gleaned from the early incoming data. The feasibility of using adaptive trial design to make informed decisions about phase III trial planning from phase II sepsis studies has recently been highlighted in clinical trial with l-carnitine for sepsis (23) .
There are a number of potential advantages to this process including the capacity to detect early and significant differences in time-related or biomarker-related outcomes. Adaptive trial design can allow for seamless transition from a phase II to a phase III clinical trial and the possibility of a continuous trial design where new drugs can be added or rejected, if deemed appropriate, to an ongoing clinical trial with an expanding placebo group database. A key component of these designs is the need to conduct pretrial simulations, which can allow investigators to better understand potential uncertainties before trial launch. Adaptive designs can potentially make greater use of pretrial simulations and generate mathematical predictions of the likelihood of success or failure in intervention trials in sepsis. The final benefit of adaptive trial design is the capacity to recommend early discontinuation of noneffective drugs, thereby sparing time, money, and human resources on nonproductive drug doses or drug choices.
Assuming that regulatory agencies support the process, adaptive trial designs should be tested in future sepsis trials, in parallel to traditional methods, to determine if adaptive methods can accurately advance research findings in sepsis research. Adaptive trial design studies are already underway in a number of ongoing clinical trials in other fields of medicine. Risks of adaptive design methods include the relative lack of experience (and suspicion) of some statisticians and many clinical investigators in the use of this methodology, the problem of distinguishing type I and type II errors, and the possible difficulties if predicted association between prespecified biomarkers and surrogate markers for primary endpoint (mortality) is not highly correlated, as anticipated at the beginning of the trial.
DO CLINICAL COORDINATING CENTERS HELP OR HINDER INTERVENTIONAL SEPSIS TRIALS?
The capacity to generate reproducible results in clinical trials is predicated upon the ability to define and repeatedly capture similar patient populations with which to test a novel intervention in multiple clinical trials. Sepsis trials are particularly challenging as the heterogeneity of the patient population changes in baseline standard of care and the lack of precision in defining specific populations from one study to another. The entry criteria written into the clinical trial protocol are supposed to define the optimal patient population, but variations in interpretation of the entry criteria by investigators continue to plague trial execution in sepsis studies.
One potential strategy to limit variability of the study population expected is to employ a central clinical coordinating center to screen potential study participants. These centers have to be available around the clock, and center personnel need to skilled clinical investigators who are very familiar with the protocol and its nuances. This is not a simple process of simply checking the boxes for entry and exclusionary criteria on an enrollment form. Clinical decisions need to be made expeditiously by knowledgeable investigators and the research team as to whether a patient is eligible or not.
There is ample evidence of a "learning curve" where the first and second patients enrolled at each site in any clinical trial where more protocol violations occur and lack of full understanding of the patient population to be studied is evident. One role of the clinical coordinating center is to shorten or eliminate the duration of this learning curve in appropriate enrollment for sepsis trials (24) .
An important aspect is the center selection. Should we only use "Centers for Excellence" who are familiar with the problems associated with clinical trials in sepsis? They see sufficiently large numbers of patients to maintain a high level of proficiency and interest in the study to assure high-quality enrollment of patients for sepsis trials. Perhaps phase II and even phase III trials should be conducted in level I sepsis clinical trial centers and expand study centers to smaller ICUs in phase IV trials. What constitutes a center for excellence has not been clearly defined. Additionally, it is not clear that there are sufficient numbers of centers for excellence to generate the large number of patients in a reasonable time period to complete large phase III trials. Furthermore, there is a question of external validity of the data if it is just done in a few high-volume centers. How well does this correlate with the field conditions within smaller ICUs scattered around the globe?
WHO SHOULD OWN THE DATA?
A simmering tension exists between clinical investigators and industry sponsors who often fund phase III sepsis trials over ownership of the data and clinical samples and specimens. The study sponsors have paid large sums of money to see the study completed and justifiably feel that ownership of the patient samples and databases are theirs alone. Intellectual property issues are understandably paramount in the eyes of study sponsors and are of little concern to most academic investigators. Clinical investigators are much more interested in interrogating large databases in septic patients to test new hypotheses. Ideally, this would allow the capacity to run new biomarker panels or a series of other diagnostic and prognostic markers on plasma and cell banks derived from existing clinical trial material. Attempts to generate a central database and form a repository for at least those patients enrolled in placebo group in sepsis trials have been argued for many years (14) . This could be open to academicians and industry alike to test new ideas and new hypotheses. The logistics are complicated but a repository of clinical, laboratory, and research data, while honoring patient confidentiality, should be a joint goal for the future as a shared database, including hemodynamic variables, plasma banks, and cell banks. The development of such "knowledge networks" that function in an open and collaborative spirit is a laudable effort and should be vigorously pursued in sepsis and acute inflammation research.
WHY HAVE SO MANY PHASE II SEPSIS TRIALS LOOK PROMISING bUT FAIL IN PHASE III TRIALS?
Significant issues remain surrounding the translation of clinical results from phase II studies to phase III trials. This has been a major stumbling block in a large number of sepsis trials dating back to the initial trials with human recombinant interleukin-1 receptor antagonist (IL-1ra) phase II trial performed 20 years ago (25) . This small, open label clinical trial demonstrated the remarkable improvement in 28-day all-cause survival with an over 50% reduction in relative risk of mortality by IL-1ra. Unfortunately, this seemingly dramatic benefit was not replicated in a phase III trial where IL-1ra did not demonstrate any significant improvement in outcome in two subsequent phase III trials (26, 27) . Similar studies with other antisepsis agents appeared to be favorable in phase II, but no significant survival benefits were confirmed in subsequent phase III trials. Small phase II trials, like phase III trials stopped early for evidence of efficacy, are systematically susceptible to overestimating beneficial treatment effects than larger trials not stopped early for efficacy (28) . In addition, phase II in sepsis have been hindered by the lack of a biomarker that the trial might be powered on and that correlates with clinically important outcome. The review of the data suggests that larger phase II trials are probably indicated to reduce the risk of studying inactive drugs in phase III studies. Large phase II trials assure that there is adequate statistical power in calculating the effect size in a phase III clinical trial.
The decision to "go" or "no go" into a phase III trial based on a phase II research program is difficult at best. This decision is often made on an emotional basis hoping to see trends in some subgroup and largely ignoring disturbing evidence of chance observations in small studies. Phase II trials in sepsis are generally underpowered to show a survival benefit, and therefore, the effect size calculations attributable to the test agent is often based on the mechanism of action studies and biologic surrogates for disease activity. The lack of reproducibility of clinical trial results in sepsis patients is the major impediment to progress in developing new drugs for sepsis. A dispassionate, realistic review of the data with due consideration for CIs needs to drive the decision to go forward or to halt further clinical development of an experimental agent.
THE PROWESS VERSUS THE PROWESS SHOCK STUDY OF ACTIVATED PROTEIN C: WHAT HAPPENED?
After all the controversy that has arisen about the efficacy of recombinant human activated protein C (rhAPC) in severe sepsis after the publication of the original human recombinant Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial (5), a second, phase III, placebo-controlled, confirmatory trial was undertaken, the PROWESS SHOCK study (6) . Theoretically, the PROWESS SHOCK study was expected to enroll more severely ill patients with a higher mortality rate than in the original PROWESS trial. Patients were required to be in fluid, nonresponsive, vasopressor-dependent (> 4 hr) septic shock with sepsis-induced organ failure. Nonetheless, a significantly lower mortality rate was observed in PROWESS SHOCK (n = 1,680) than in the original PROW-ESS (n = 1,290) placebo-treated groups (24.2% [PROWESS SHOCK] vs 30.8% [PROWESS] ). Regrettably, the mortality rate in the rhAPC-treated group did not change substantially from 24.7% in PROWESS to 26.4% in PROWESS SHOCK. The end result was that the highly statistically significant improvement in 28-day outcome with rhAPC over placebo in the original study (p = 0.006) was not confirmed in the PROWESS SHOCK study (p = 0.31). For this reason, rhAPC has now been taken off the market.
What accounts for the differences in these two studies? The two studies are separated by approximately 10 years and improvements in supportive care have occurred during this period of time. It is of interest to speculate how other approved drugs might fare if put to the test again 10 years after approval. Would the incremental benefits attributed to the drug be confirmed or lost over time as a result of progressive improvement in background therapy and outcomes in ICU supportive care. The standard of care has improved for septic patients worldwide through the introduction of the Surviving Sepsis Campaign Guidelines (29) . Bundled care with protocolized receipt of early and appropriate antibiotics for patients with septic shock is clearly associated with improved outcomes (30) . This may account for the improved placebo event rate, but it does not explain the lack of similar decline in mortality rate that might have been expected in the rhAPC-treated group. Another potential explanation is the fact that the confirmatory PROWESS SHOCK study was not repeated in many of the same institutions that participated in PROWESS. In fact, many institutions where rhAPC was regularly used did not participate in the PROWESS SHOCK study. It is difficult to consider clinical equipoise between treatment and placebo in a situation in which rhAPC was an approved drug that had been shown to save lives in severely septic patients based on the PROWESS trial results. This issue of equipoise was particularly problematic in the Administration of Drotrecogin alfa [activated] in Early stage Severe Sepsis trial in which activated protein C was studied in patients with sepsis at low risk of death (31) . In this study, patients in the lowest quartile of risk were specifically studied to determine if the trend observed in the original PROWESS trial, namely, worse outcome with rhAPC versus placebo, was confirmed or refuted in the follow-up trial.
The PROWESS SHOCK investigators were chosen because they often were not convinced that the survival advantage of PROWESS and thought the efficacy of the drug was still in question. The net effect of this study issue was the removal of a number of experienced centers of excellence that would have participated in the PROWESS study and the addition of a number of smaller ICU sites to contribute to the trial. The impact of this change in study sites selected for PROWESS SHOCK is unknown but is worth serious consideration. The learning curve observed in the first phase III trial (24) had to recur in each of the new investigative sites for the second phase III trial. A recent critique of PROWESS and PROWESS SHOCK by Kalil and Florescu (32) points out a myriad of significant differences in the patient characteristics and clinical care delivered to the two study populations by a statistical heterogeneity analysis. The two studies are not comparable by a number of highly relevant, clinical elements that could impact survival, independent of receipt of rhAPC therapy. This analytical review and the favorable results from a combination of a large series of pragmatic trials with rhAPC (n = 41,401 patients) suggest that further clinical trials or at least an individual patient data meta-analysis of all rhAPC studies should be done (32, 33) .
CONCLUSIONS AND RECOMMENDATIONS
Sepsis and septic shock are not going away; in fact, the evidence is quite the opposite. A recent report from the Centers for Disease Control and Prevention suggests that the prevalence continues to climb in the United States (34) . As the aggregate age of the population increases, the prevalence of sepsis will likely increase. Similar demographics and trends are found worldwide and the public health consequences of sepsis are only beginning to be fully recognized.
Sepsis survivors spend significantly longer in acute care hospitals and longer length of stays in ICUs than patients admitted with other diagnoses. Septic patients are also more likely to need extended care in other acute or long-term, healthcare facilities upon discharge than patients admitted with other diagnoses (36% vs 14%). An estimated 14.6 billion dollars were spent in the United States in 2008 in direct patient care of sepsis/septicemia (35) . The cost to society in terms of loss of life, productivity, and loss of quality of life from physical and cognitive impairment due to sepsis is staggering (34, 35) .
Coming up with improved therapies for sepsis will not be easy for this complex, heterogeneous, and rapidly evolving clinical syndrome that comprises an array of disparate diseases, different pathogens, and comorbid illnesses (36) (37) (38) (39) . Hopeful signs are beginning to appear, suggesting that new approaches to the problem of sepsis studies might be on the horizon (40) (41) (42) . Perhaps the more intelligent use of point of care, rapid assays with biomarker panels to predictive responsiveness to specific therapies, and improved trial designs can increase the chance for success in the future (43) . Our current developmental paradigm is not working and demands we change our direction. We suggest that the following recommendations be considered in changing the current skepticism into finding new drugs to treat sepsis with a reasonable chance of success (Table 1) . Our patients need better treatments. We should rethink what we are doing but definitely not give up.
